Artiva Biotherapeutics (ARTV) Change in Accured Expenses (2023 - 2026)
Artiva Biotherapeutics (ARTV) reported Change in Accured Expenses of -$4.0 million for Q1 2026, down 329.97% year-over-year from $1.7 million in Q1 2025, and down 269.26% quarter-over-quarter from $2.4 million in Q4 2025.
Artiva Biotherapeutics (ARTV) Change in Accured Expenses (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 4 years of Change in Accured Expenses data on file, last reported at -$4.0 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$4.0 million, down 329.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 173.62% YoY), and the FY2025 annual result was $2.0 million, up 403.95% from the prior year.
- Change in Accured Expenses declined to -$4.0 million in Q1 2026 per ARTV's latest filing, from $2.4 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $3.1 million in Q3 2024 and troughed at -$4.0 million in Q1 2026.
- A 4-year average of -$261363.6 and a median of -$359000.0 in 2023 frame the typical range for Change in Accured Expenses.
- On a YoY basis, Change in Accured Expenses climbed as much as 964.07% in 2024 and fell as far as 793.71% in 2024.
- A 4-year view of Change in Accured Expenses shows it stood at $143000.0 in 2023, then plunged by 793.71% to -$992000.0 in 2024, then soared by 338.41% to $2.4 million in 2025, then tumbled by 269.26% to -$4.0 million in 2026.
- Business Quant data shows ARTV's Change in Accured Expenses at -$4.0 million in Q1 2026, $2.4 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Artiva Biotherapeutics | 241.85 Mn | 241.85 Mn | - | -4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.00 Mn |
| Mar 31, 2026 | -4.00 Mn |
| Dec 31, 2025 | 2.37 Mn |
| Dec 31, 2025 | 2.37 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | -550,000.00 |
| Jun 30, 2025 | -550,000.00 |
| Mar 31, 2025 | -931,000.00 |
| Mar 31, 2025 | -931,000.00 |
| Dec 31, 2024 | -992,000.00 |
| Dec 31, 2024 | -992,000.00 |
| Sep 30, 2024 | 3.10 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 273,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Mar 31, 2024 | -3.04 Mn |
| Mar 31, 2024 | -3.04 Mn |
| Dec 31, 2023 | 143,000.00 |
| Dec 31, 2023 | 143,000.00 |